VERA

Vera Therapeutics Inc

VERA, USA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

https://veratx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VERA
stock
VERA

Vera Therapeutics director buys $250K in common stock TipRanks

Read more →
VERA
stock
VERA

Patrick Enright Acquires 5,882 Shares of Vera Therapeutics (NASDAQ:VERA) Stock MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$62.8462

Analyst Picks

Strong Buy

9

Buy

4

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

7.97

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-20.13 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-15.52 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.30

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 100.95% of the total shares of Vera Therapeutics Inc

1.

venBio Select Advisor LLC

(9.8709%)

since

2025/06/30

2.

T. Rowe Price Associates, Inc.

(7.0189%)

since

2025/06/30

3.

BlackRock Inc

(6.5266%)

since

2025/06/30

4.

Kynam Capital Management, LP

(5.3693%)

since

2025/06/30

5.

Deerfield Management Co

(5.2459%)

since

2025/06/30

6.

Vestal Point Capital LP

(4.8571%)

since

2025/06/30

7.

Vanguard Group Inc

(4.7022%)

since

2025/06/30

8.

FMR Inc

(4.5594%)

since

2025/06/30

9.

Sofinnova Ventures

(4.3777%)

since

2025/06/30

10.

Woodline Partners LP

(4.0868%)

since

2025/06/30

11.

Eversept Partners, LLC

(3.7338%)

since

2025/06/30

12.

Morgan Stanley - Brokerage Accounts

(3.5069%)

since

2025/06/30

13.

State Street Corp

(3.1613%)

since

2025/06/30

14.

US Small-Cap Growth II Equity Comp

(2.4455%)

since

2025/06/30

15.

Vanguard Total Stock Mkt Idx Inv

(2.3552%)

since

2025/07/31

16.

TANG CAPITAL MANAGEMENT LLC

(2.1152%)

since

2025/06/30

17.

Geode Capital Management, LLC

(2.029%)

since

2025/06/30

18.

iShares Russell 2000 ETF

(1.9366%)

since

2025/08/31

19.

Fidelity Growth Compy Commingled Pl S

(1.8659%)

since

2025/07/31

20.

Integral Health Asset Management, LLC

(1.8018%)

since

2025/06/30

21.

T. Rowe Price New Horizons

(1.7379%)

since

2025/07/31

22.

Fidelity Growth Company Fund

(1.3768%)

since

2025/07/31

23.

SPDR® S&P Biotech ETF

(1.3757%)

since

2025/08/31

24.

T. Rowe Price Health Sciences

(1.2645%)

since

2025/07/31

25.

COMMODORE CAPITAL LP

(1.2535%)

since

2025/06/30

26.

Pictet Asset Manangement SA

(1.2109%)

since

2025/06/30

27.

American Century Companies Inc

(1.1194%)

since

2025/06/30

28.

International Biotechnology Ord

(1.0578%)

since

2025/08/31

29.

Rock Springs Capital Management LP

(0.9673%)

since

2025/06/30

30.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9326%)

since

2025/07/31

31.

American Century U.S. Small Cap Growth

(0.8839%)

since

2025/06/30

32.

American Century Small Cap Growth Inv

(0.8839%)

since

2025/06/30

33.

Fidelity Small Cap Index

(0.8091%)

since

2025/06/30

34.

T. Rowe Price New Horizons Tr-A

(0.7905%)

since

2025/06/30

35.

iShares Russell 2000 Growth ETF

(0.7099%)

since

2025/08/31

36.

T. Rowe Price Integrated US Sm Gr Eq

(0.6571%)

since

2025/07/31

37.

T. Rowe Price Integrated US SmCapGrEq

(0.6571%)

since

2025/06/30

38.

Pictet-Biotech P USD

(0.6125%)

since

2025/05/31

39.

Fidelity Select Biotechnology

(0.6106%)

since

2025/07/31

40.

Xtrackers S&P 500 Swap ETF 1C

(0.4747%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-1.3

Latest Release

Date

2025-09-30

EPS Actual

-1.26

EPS Estimate

-1.15

EPS Difference

-0.11

Surprise Percent

-9.5652%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.